Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward ...

Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of ...

Figures around September 29, 2026. Due to variations in dates and times across sources, closing prices for some stocks cannot ...

Liquidia Corporation LQDA and Alkermes plc ALKS are both commercial-stage biopharmaceutical companies with specialty ...

Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the ...

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

All that has changed, and if you want to invest in growth away from AI, biotech might be where you want to be. Below, I will attempt to lay out the various macro and policy disruptions that had a ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it, the ...

KOD surged 178% Monday to $89.92, its best day on record and highest close since December 2021. ・Kodiak said its separate eye drugs Zenkuda and KSI-501 met the primary endpoints in the Phase 3 ...

The company's stock rose to a 52-week high of $9.35 on Wednesday. Last week, the company introduced the Fill-Tek Dispensing System for essential custom reagents, designed to ease bioprocessing ...

The company's stock soared over 177% on Monday to a new 52-week high of $95.77. On the same day, Kodiak reported that the Phase 3 DAYBREAK trial evaluating its lead drug Zenkuda achieved its primary ...